Cytek Biosciences (CTKB) Share-based Compensation (2020 - 2026)

Cytek Biosciences has reported Share-based Compensation for 7 years, with the latest figure at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 26.68% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $22.8 million (down 18.04% YoY), and the FY2025 full-year result was $24.6 million, down 8.43% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.9 million, down from $5.5 million in the prior quarter.
• The five-year high for Share-based Compensation was $7.2 million in Q2 2024, with the low at $3.8 million in Q1 2022.
• Historically, Share-based Compensation has averaged $5.6 million across 5 years, with a median of $5.6 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 741.45% — and 2026, when it decreased 26.68%.
• Cytek Biosciences' Share-based Compensation stood at $4.5 million in 2022, then increased by 26.97% to $5.7 million in 2023, then climbed by 23.53% to $7.0 million in 2024, then slipped by 21.08% to $5.5 million in 2025, then declined by 12.05% to $4.9 million in 2026.
• The last three Share-based Compensation figures came in at $4.9 million (Q1 2026), $5.5 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.